Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the... see more

Recent & Breaking News (NDAQ:RIGL)

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

PR Newswire December 21, 2021

Rigel Appoints Kamil Ali-Jackson to Board of Directors

PR Newswire December 16, 2021

Rigel Sharpens Focus on Its Advanced Portfolio Opportunities

PR Newswire November 15, 2021

Rigel to Participate in Two Upcoming Investor Conferences

PR Newswire November 9, 2021

Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update

PR Newswire November 2, 2021

Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update

PR Newswire October 26, 2021

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 8, 2021

Rigel to Participate in Three Upcoming Investor Conferences

PR Newswire September 2, 2021

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases

PR Newswire September 1, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL

Newsfile August 17, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL

PR Newswire August 16, 2021

Rigel Pharmaceuticals Provides Update on COVID-19 Program

PR Newswire August 13, 2021

Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update

PR Newswire August 3, 2021

Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update

PR Newswire July 27, 2021

New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

PR Newswire July 14, 2021

Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial

PR Newswire June 29, 2021

Rigel to Present at the Jefferies Virtual Healthcare Conference

PR Newswire May 26, 2021

Rigel Appoints Alison L. Hannah, M.D. to Board of Directors

PR Newswire May 14, 2021

Rigel Reports First Quarter 2021 Financial Results and Provides Business Update

PR Newswire May 5, 2021

Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

PR Newswire April 28, 2021